Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
305.45M | 202.57M | 234.69M | 212.19M | 179.32M | Gross Profit |
194.40M | 60.62M | -26.75M | -16.60M | 4.03M | EBIT |
-23.21M | -163.66M | -667.65M | -446.15M | -241.99M | EBITDA |
-23.21M | -136.46M | -398.20M | -219.19M | -224.73M | Net Income Common Stockholders |
-52.29M | -175.77M | -548.98M | -245.39M | -246.44M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
141.19M | 130.15M | 123.93M | 400.57M | 108.13M | Total Assets |
419.38M | 473.67M | 490.94M | 554.09M | 251.64M | Total Debt |
64.25M | 119.77M | 72.38M | 32.85M | 45.02M | Net Debt |
-20.96M | 20.09M | -51.55M | -367.72M | -63.11M | Total Liabilities |
174.13M | 245.66M | 237.24M | 165.99M | 581.69M | Stockholders Equity |
245.25M | 228.02M | 253.71M | 388.10M | -330.05M |
Cash Flow | Free Cash Flow | |||
-33.99M | -185.86M | -333.48M | -211.22M | -125.10M | Operating Cash Flow |
-28.50M | -180.15M | -319.15M | -190.43M | -93.13M | Investing Cash Flow |
-30.13M | -43.73M | -141.33M | -20.79M | -31.97M | Financing Cash Flow |
44.16M | 186.24M | 197.31M | 493.73M | 129.06M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $8.54B | 106.06 | 2.27% | ― | 0.66% | ― | |
60 Neutral | $2.45B | 38.75 | -22.10% | ― | 50.79% | 73.57% | |
53 Neutral | $8.52B | ― | -37.09% | ― | 10.37% | -389.98% | |
53 Neutral | $5.26B | ― | -4584.47% | ― | 31.04% | 16.91% | |
51 Neutral | $935.92M | ― | -17.15% | ― | 12.15% | 61.33% | |
49 Neutral | $13.39B | ― | -30.11% | ― | -2.93% | -4.69% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% |
GeneDx Holdings Corp. announced its preliminary, unaudited financial results for the fourth quarter and full year of 2024, indicating expectations to exceed its revenue guidance with at least $299 million for the year and $92 million for the fourth quarter. The company also anticipates a full year adjusted gross margin of at least 64% and 68% in the fourth quarter, highlighting strong execution and profitability milestones, including positive operational cash flow and adjusted net income, positioning itself as a standard-bearer in the use of genetics in healthcare.
GeneDx Holdings Corp. announced the appointment of Bryan Dechairo as Chief Operating Officer, a role in which he will oversee key areas including Product & Technology and Operations, as part of the company’s strategy to drive commercial growth and enhance health outcomes through genomic insights. Dr. Dechairo, with over 30 years of experience in diagnostics and pharmaceuticals, is expected to lead operational excellence and accelerate the adoption of genomic insights, positioning GeneDx for growth and scaling its market-leading position in pediatric genetics.